|
Shunji Endo
Department Kawasaki Medical School Kawasaki Medical School, Department of Digestive Surgery, Position Associate Professor |
|
| Article types | 原著 |
| Language | English |
| Peer review | Peer reviewed |
| Title | Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202. |
| Journal | Formal name：Anticancer research Abbreviation：Anticancer Res ISSN code：17917530/02507005 |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 39(2),pp.1059-1065 |
| Author and coauthor | Endo Shunji, Kurokawa Yukinori, Gamoh Makio, Kimura Yutaka, Matsuyama Jin, Taniguchi Hirokazu, Takeno Atsushi, Kawabata Ryohei, Kawada Junji, Masuzawa Toru, Yamamoto Kazuyoshi, Kobayashi Kouji, Sakai Daisuke, Shimokawa Toshio, Satoh Taroh |
| Authorship | Lead author |
| Publication date | 2019/02 |
| Summary | BACKGROUND/AIM:Trastuzumab with S-1 plus cisplatin was proved to be effective for human epidermal growth factor receptor type 2 (HER2)-positive advanced gastric cancer with measurable lesions. However, the efficacy and safety of this regimen in the absence of measurable lesions are unknown.PATIENTS AND METHODS:Patients with HER2-positive gastric cancer without measurable lesions received cisplatin plus trastuzumab intravenously on day 1 and oral S-1 on days 1-14 of a 21-day cycle. The primary end-point was overall survival, and 40 patients were planned to be enrolled.RESULTS:Fifteen patients were enrolled. The median overall survival was 14.4 months. The 1- and 3-year overall survival rates were 66.7 % and 26.7 %, respectively. Major grade 3-4 adverse events included neutropenia (47%), anemia (40%), diarrhea (20%), nausea (20%), and anorexia (20%).CONCLUSION:Trastuzumab with S-1 plus cisplatin might be effective and tolerable for HER2-positive advanced gastric cancer without measurable lesions. |
| DOI | 10.21873/anticanres.13213 |
| PMID | 30711995 |